Campaigners are calling on pharmaceutical company Roche to cut the price of a pioneering new breast cancer treatment amid indications the NHS drugs watchdog is set to reject its use on the service on cost grounds. NICE said the £90,000 cost of trastuzumab emtansine is not justifiable. Sir Andrew Dillon, NICE Chief Executive, said: “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.”
If you would like to understand what these developments mean, please get in touch with our specialist team.
Related
